Treatment selection in metastatic renal cell carcinoma: expert consensus (original) (raw)

• Sun, M. et al. Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur. Urol. 59, 135–141 (2011).
  Article PubMed Google Scholar
• McDermott, D. F. & Rini, B. I. Immunotherapy for metastatic renal cell carcinoma. BJU Int. 99, 1282–1288 (2007).
  Article CAS PubMed Google Scholar
• Rini, B. I., Campbell, S. C. & Escudier, B. Renal cell carcinoma. Lancet 373, 1119–1132 (2009).
  Article CAS PubMed Google Scholar
• Escudier, B. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125–134 (2007).
  Article CAS PubMed Google Scholar
• Motzer, R. J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115–124 (2007).
  Article CAS PubMed Google Scholar
• Sternberg, C. N. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 28, 1061–1068 (2010).
  Article CAS PubMed Google Scholar
• Rini, B. I. et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378, 1931–1939 (2011).
  Article CAS PubMed Google Scholar
• Escudier, B. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370, 2103–2111 (2007).
  Article PubMed Google Scholar
• Rini, B. I. et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J. Clin. Oncol. 28, 2137–2143 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449–456 (2008).
  Article CAS PubMed Google Scholar
• Hudes, G. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271–2281 (2007).
  Article CAS PubMed Google Scholar
• Porta, C. et al. Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement. Med. Oncol. 2011 Jul 7. [Epub ahead of print] http://dx.doi.org/10.1007/s12032-011-0016-8.
• Plaza-Menacho, I. et al. Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J. Biol. Chem. 282, 29230–29240 (2007).
  Article CAS PubMed Google Scholar
• Roskoski, R. Jr. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem. Biophys. Res. Commun. 356, 323–328 (2007).
  Article CAS PubMed Google Scholar
• Sonpavde, G., Hutson, T. E. & Rini, B. I. Axitinib for renal cell carcinoma. Expert Opin. Investig. Drugs 17, 741–748 (2008).
  Article CAS PubMed Google Scholar
• Sonpavde, G., Hutson, T. E. & Sternberg, C. N. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert Opin. Investig. Drugs 17, 253–261 (2008).
  Article CAS PubMed Google Scholar
• Wilhelm, S. M. et al. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099–7109 (2004).
  Article CAS PubMed Google Scholar
• Wilhelm, S. M. et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 7, 3129–3140 (2008).
  Article CAS PubMed Google Scholar
• Chowdhury, S. et al. Systemic therapy for metastatic nonclearcell renal cell carcinoma: recent progress and future directions. Hematol. Oncol. Clin. North Am. 25, 853–869 (2011).
  Article PubMed PubMed Central Google Scholar
• Patard, J. J. et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J. Clin. Oncol. 23, 2763–2771 (2005).
  Article PubMed Google Scholar
• Dutcher, J. P. et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med. Oncol. 26, 202–209 (2009).
  Article CAS PubMed Google Scholar
• Motzer, R. J. et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17, 2530–2540 (1999).
  Article CAS PubMed Google Scholar
• Motzer, R. J., Bacik, J., Murphy, B. A., Russo, P. & Mazumdar, M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 20, 289–296 (2002).
  Article CAS PubMed Google Scholar
• Heng, D. Y. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol. 27, 5794–5799 (2009).
  Article CAS PubMed Google Scholar
• Heng, D. Y. et al. External validation of the International Metastatic Renal Cell Carcinoma (mRCC) Database Consortium prognostic model and comparison to four other models in the era of targeted therapy [abstract]. J. Clin. Oncol. 29 (Suppl.), a4560 (2011).
  Article Google Scholar
• Manola, J. et al. Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the International Kidney Cancer Working Group. Clin. Cancer Res. 17, 5443–5450 (2011).
  Article PubMed PubMed Central Google Scholar
• Crepel, M. et al. Comparison of two major prognostic models for patients with metastatic renal cell carcinoma treated in the contemporary era of targeted therapies [abstract]. J. Clin. Oncol. 29 (Suppl.), a4660 (2011).
  Article Google Scholar
• Eisen, T. et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J. Natl Cancer Inst. 100, 1454–1463 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Hutson, T. E. et al. A pooled analysis of the efficacy and safety of sunitinib in elderly patients (pts) with metastatic renal cell carcinoma (mRCC) [abstract]. J. Clin. Oncol. 29 (Suppl.), a4604 (2011).
  Article Google Scholar
• Porta, C. et al. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD1 trial. Eur. Urol. 61, 826–833 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• [No authors listed] Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 353, 14–17 (1999).
• Klapper, J. A. et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 113, 293–301 (2008).
  Article CAS PubMed Google Scholar
• McDermott, D. F. et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 23, 133–141 (2005).
  Article CAS PubMed Google Scholar
• Yang, J. C. et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 21, 3127–3132 (2003).
  Article CAS PubMed Google Scholar
• Negrier, S. et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N. Engl. J. Med. 338, 1272–1278 (1998).
  Article CAS PubMed Google Scholar
• Fisher, R. I., Rosenberg, S. A. & Fyfe, G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J. Sci. Am. 6 (Suppl. 1), S55–S57 (2000).
  PubMed Google Scholar
• McDermott, D. F. et al. The high-dose aldesleukin (HD IL2) “SELECT” trial in patients with metastatic renal cell carcinoma (mRCC) [abstract]. J. Clin. Oncol. 28 (Suppl. 15), a4514 (2010).
  Article Google Scholar
• Naito, S. et al. Kidney Cancer Working Group report. Jpn. J. Clin. Oncol. 40 (Suppl. 1), i51–i56 (2010).
  Article PubMed Google Scholar
• Naito, S. et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur. Urol. 57, 317–325 (2010).
  Article CAS PubMed Google Scholar
• Motzer, R. J. et al. Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial [abstract]. J. Clin. Oncol. 29 (Suppl. 7), LBA308 (2011).
  Article Google Scholar
• Negrier, S. et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol. 12, 673–680 (2011).
  Article CAS PubMed Google Scholar
• Plimack, E. R. et al. Sunitinib in papillary renal cell carcinoma (pRCC): Results from a single-arm phase II study [abstract]. J. Clin. Oncol. 28 (Suppl. 15), a4604 (2010).
  Article Google Scholar
• Molina, A. M. et al. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Invest. New Drugs 30, 335–340 (2012).
  Article CAS PubMed Google Scholar
• Ravaud, A. et al. First-line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase trials (GEP) [abstract]. J. Clin. Oncol. 27 (Suppl. 15), a5146 (2009).
  Google Scholar
• Gore, M. E. et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 10, 757–763 (2009).
  Article CAS PubMed Google Scholar
• Motzer, R. J. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584–3590 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• US National Library of Medicine. ClinicalTrials.gov [online], (2012).
• US National Library of Medicine. ClinicalTrials.gov [online], (2011).
• Rini, B. I. et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol. 26, 5422–5428 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• US National Library of Medicine. ClinicalTrials.gov [online], (2012).
• Escudier, B. et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 1280–1289 (2009).
  Article CAS PubMed Google Scholar
• Jonasch, E. et al. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 116, 57–65 (2010).
  CAS PubMed Google Scholar
• Procopio, G. et al. Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. Br. J. Cancer 104, 1256–1261 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Rini, B. I. et al. AMG 386 in combination with sorafenib in patients (pts) with metastatic renal cell cancer (mRCC): A randomized, double-blind, placebo-controlled, phase II study [abstract]. J. Clin. Oncol. 29 (Suppl. 7), a309 (2011).
  Article Google Scholar
• US National Library of Medicine. ClinicalTrials.gov [online], (2012).
• US National Library of Medicine. ClinicalTrials.gov [online], (2011).
• US National Library of Medicine. ClinicalTrials.gov [online], (2012).
• Escudier, B. et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol. 27, 3312–3318 (2009).
  Article CAS PubMed Google Scholar
• Stadler, W. M. et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 116, 1272–1280 (2010).
  Article CAS PubMed Google Scholar
• Beck, J. et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann. Oncol. 22, 1812–1823 (2011).
  Article CAS PubMed Google Scholar
• Tolcher, A. W. et al. A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother. Pharmacol. 67, 751–764 (2011).
  Article CAS PubMed Google Scholar
• Bellmunt, J., Fishman, M., Eisen, T. & Quinn, D. Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients. Expert. Rev. Anticancer. Ther. 10, 825–835 (2010).
  Article CAS PubMed Google Scholar
• Escudier, B. & Kataja, V. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21 (Suppl. 5), v137–v139 (2010).
  Article PubMed Google Scholar
• National Comprehensive Cancer Network®. NCCN clinical practice guidelines in oncology: Kidney cancer. v.2.2011 [online], (2012).
• Melichar, B. et al. BEVLiN: Prospective study of the safety and efficacy of first-line bevacizumab (BEV) plus low-dose interferon-a2a (IFN) in patients (pts) with metastatic renal cell carcinoma (mRCC) [abstract]. J. Clin. Oncol. 29 (Suppl.), a4546 (2011).
  Article Google Scholar
• Bukowski, R. M. et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J. Clin. Oncol. 25, 4536–4541 (2007).
  Article CAS PubMed Google Scholar
• Garcia, J. A. et al. Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial. BJU Int. 107, 562–570 (2011).
  Article PubMed Google Scholar
• Motzer, R. J. et al. Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. Clin. Genitourin. Cancer 7, 28–33 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Grunwald, V. et al. A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC). Acta Oncol. 50, 121–126 (2011).
  Article PubMed CAS Google Scholar
• Bracarda, S. et al. Elderly patients with advanced renal cell carcinoma (RCC) successfully treated [abstract 142]. Eur. Urol. Suppl. 8, 156 (2009).
  Article Google Scholar
• Gollob, J. A. et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J. Clin. Oncol. 25, 3288–3295 (2007).
  Article CAS PubMed Google Scholar
• Ryan, C. W. et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J. Clin. Oncol. 25, 3296–3301 (2007).
  Article CAS PubMed Google Scholar
• Bracarda, S. et al. Randomized prospective phase II trial of two schedules of sorafenib daily and interferon-a2a (IFN) in metastatic renal cell carcinoma (MRCC) (RAPSODY): GOIRC Study 0681 [abstract]. J. Clin. Oncol. 25 (Suppl.), a5100 (2007).
  Google Scholar
• Wang, S. et al. Safety and treatment (trx) patterns of angiogenesis inhibitors (AIs) in patients (pts) with metastatic renal cell carcinoma (mRCC): evidence from US community oncology clinics [abstract 7143]. Eur. J. Cancer Suppl. 7, 465 (2009).
  Google Scholar
• Buchler, T. et al. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma --data from the Czech registry. Ann. Oncol. 23, 395–401 (2012).
  Article CAS PubMed Google Scholar
• Calvani, N. et al. Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: does the order of sequencing matter? Med. Oncol. http://dx.doi.org/10.1007/s12032-011-0048-0.
• Choueiri, T. K., Brick, A. J., McDermott, D. & Clement, J. Treatment and dosing patterns for angiogenesis inhibitor (AIs) therapies in patients with metastatic renal cell carcinoma (mRCC) [abstract 593P ]. Ann. Oncol. 19 (Suppl. 8), viii191 (2008).
  Google Scholar
• Dudek, A. Z., Zolnierek, J., Dham, A., Lindgren, B. R. & Szczylik, C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 115, 61–67 (2009).
  Article CAS PubMed Google Scholar
• Eichelberg, C. et al. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur. Urol. 54, 1373–1378 (2008).
  Article CAS PubMed Google Scholar
• Merseburger, A. S., Simon, A., Waalkes, S. & Kuczyk, M. A. Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer. Expert Rev. Anticancer. Ther. 9, 1429–1434 (2009).
  Article CAS PubMed Google Scholar
• Porta, C. et al. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int. 8 (Pt 2), E250–E257 (2011).
  Article Google Scholar
• Sablin, M. P. et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J. Urol. 182, 29–34 (2009).
  Article CAS PubMed Google Scholar
• Tamaskar, I. et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J. Urol. 179, 81–86 (2008).
  Article CAS PubMed Google Scholar
• Feinberg, B. A. et al. Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics. Med. Oncol. http://dx.doi.org/10.1007/s12032-011-9922-z.
• Zimmermann, K. et al. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 76, 350–354 (2009).
  Article CAS PubMed Google Scholar
• Richter, S. et al. Long-term therapy with sunitinib and sorafenib in patients with metastasizing renal cell carcinoma [abstract]. J. Clin. Oncol. 29 (Suppl. 7), a407 (2011).
  Article Google Scholar
• Motzer, R. J. et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116, 4256–4265 (2010).
  Article CAS PubMed Google Scholar
• Levy, A. et al. Treatment (trx) modalities after a front line targeted therapies in patients (pts) with metastatic renal cell carcinoma (mRCC) [abstract 7153]. Eur. J. Cancer 47, S521 (2011).
  Article Google Scholar
• Rini, B. I. et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J. Clin. Oncol. 27, 4462–4468 (2009).
  Article CAS PubMed Google Scholar
• Paez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220–231 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Choueiri, T. K. et al. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. BJU Int. 105, 1247–1254 (2010).
  Article PubMed Google Scholar
• Filson, C. P., Redman, B. G., Dunn, R. L. & Miller, D. C. Initial patterns of care with oral targeted therapies for patients with renal cell carcinoma. Urology 77, 825–830 (2011).
  Article PubMed Google Scholar
• Zama, I. N. et al. Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer 116, 5400–5406 (2010).
  Article CAS PubMed Google Scholar
• Nozawa, M. et al. Activity of retreatment with sorafenib for metastatic renal cell carcinoma [abstract]. J. Clin. Oncol. 29 (Suppl. 7), a404 (2011).
  Article Google Scholar
• Al-Marrawi, M. Y. et al. The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients (pts) [abstract]. J. Clin. Oncol. 29 (Suppl.), a4555 (2011).
  Article Google Scholar
• US National Library of Medicine. ClinicalTrials.gov [online], (2012).
• US National Library of Medicine. ClinicalTrials.gov [online], (2012).
• US National Library of Medicine. ClinicalTrials.gov [online], (2011).
• Albiges, L. et al. Prognosis of patients with metastatic renal cell carcinoma (mRCC) with primary resistance to sunitinib: is there any active treatment [abstract]? Eur. J. Cancer 47, a7143 (2011).
  Google Scholar
• Heng, D. Y. et al. Primary antiVEGFrefractory metastatic renal cell carcinoma (mRCC): Clinical characteristics, risk factors, and subsequent therapy [abstract]. J. Clin. Oncol. 29 (Suppl. 7), a305 (2011).
  Article Google Scholar